Could a hormone shot boost IVF success for women with endometriosis?
NCT ID NCT04356664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving a GnRH agonist before a frozen embryo transfer can help women with endometriosis or adenomyosis get pregnant. About 180 women aged 18 to 36 will be randomly assigned to receive either standard hormone support or standard support plus one or two doses of GnRH agonist. The main goal is to see if the extra treatment increases the rate of clinical pregnancy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 180 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2021
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 36 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women aged 18 to 36 years (women ≥18 years to \<36 years) with endometriosis and / or adenomyosis * Having benefited from In vitro fertilisation /intracytoplasmic micro-injection with freeze all and for whom the frozen embryon transfer of a blastocyst is planned * A normal uterine cavity * An MRI showing endometriosis and / or adenomyosis during the inclusion visit * Having signed a consent form * Being affiliated to a Health Insurance Plan. Exclusion Criteria: * Patient aged \<18 years and ≥ 36 years * BMI\> 35 * History of implantation failures (≥ 2) * Endometrial alterations: synechiae, polyps, myomas, hyperplasia, hematometra * known hydrosalpinx uni or bilateral * MRI showing no endometriosis or adenomyosis * Hypersensitivity to GnRH, GnRH analogues, or any of the excipients of Decapeptyl 3 mg * Known hypersensitivity to estradiol * Known hypersensitivity to progesterone * Known hypersensitivity to acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs * Known hypersensitivity to folic acid * Known hypersensitivity to cefixime or an antibiotic in the cephalosporin group * Known hypersensitivity to levofloxacin or any other quinolone * History of tendinopathies related to the administration of fluoroquinolones * Epilepsy * Hypersensitivity to contrast agents for MRI * Known or suspected breast cancer or history of breast cancer * Known or suspected genital tract cancer or history of genital cancer * known or suspected estrogen-dependent malignant neoplasms * Undiagnosed genital haemorrhage * Untreated endometrial hyperplasia * History of idiopathic venous thrombo-embolic accident or evolving venous thrombo-embolic event (deep vein thrombosis, pulmonary embolism) * Recent or evolving arterial thromboembolic stroke (eg angina, myocardial infarction) * Acute liver disease or history of liver disease, until hepatic tests are normalized * Severe renal insufficiency * Severe, uncontrolled heart failure * Evolutionary gastroduodenal ulcer * History of asthma caused by the administration of salicylates or substances of similar activity, especially nonsteroidal anti-inflammatory drugs * GnRH Agonist Decapeptyl administered within 6 months prior to transfer * To be deprived of liberty or under guardianship * Pregnancy and breast feeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adenomyosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hopital Foch
RECRUITINGSuresnes, 92150, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery pelvic floor therapy stop endometriosis pain after the operation?
- Appendix: the hidden driver of endometriosis pain?
- Antioxidant supplement tested as fertility booster for PCOS
- Allergy pill put to the test against endometriosis pain
- Do infertility treatments leave a metabolic mark on children?
- Can ultrasound and tissue clues reveal which endometriosis lesions carry cancer risk?